Join our daily newsletter At The Bell to receive exclusive market insights
- ImpediMed (IPD) has released a new heart failure and renal disease software for its SOZO Digital Health Platform
- This new software, which is called HF-Dex, is used to assess an abundance of fluid in patients with heart failure
- This data provides valuable information to physicians and allows them to provide the appropriate medication and therapy when needed
- It is hoped that by being integrated into the SOZO platform, patients with heart failure and renal disease can be provided with an accurate, non-invasive, personalised, and cost-friendly medical imaging assessment
- Despite this advance, ImpediMed shares are only up a slight 2.86 per cent and trading for 3.6 cents each
ImpediMed (IPD) has released a new heart failure and renal disease software for its SOZO Digital Health Platform.
This new software, which is called HF-Dex, is used for assessing an abundance of fluid in patients with heart failure. The information is collected and analysed against guidelines and the appropriate fluid volume found in healthy people.
This data provides valuable information to physicians, allowing them to monitor the condition of the patient and provide the appropriate medication and therapy when needed.
“Despite recent advances in treatment and management, heart failure continues to result in a high level of hospital readmissions and patient mortality,” Emergency Medicine Physician at Scripps Memorial Hospital in San Diego, Dr Andrew Accardi commented.
“We need better tools to easily and accurately assess changes in a patient’s condition. The data we are generating with SOZO is so promising, I expect it will have a very positive impact on patient care,” he said.
According to the Heart Foundation, cardiovascular disease is one of Australia’s largest health problems, killing one Australian every 12 minutes.
As well as the roll-out of HF-Dex, the new software also includes an assessment for patients with end-stage renal disease (ESRD).
ESRD is the last stage of kidney failure when they have stopped working well by themselves and now need a transplant or dialysis to function.
According to Kidney Health Australia, approximately 1.7 million Australian’s over the age of 18 have indicators of kidney disease.
However, less than 10 per cent know they have a problem which means that over 1.5 million are unaware that something is wrong.
It is hoped that by being integrated into ImpediMed’s SOZO platform, patients with heart failure and ESRD can be provided with an accurate, non-invasive, and cost-friendly alternative.
“With this new software, we are bringing the benefits of SOZO to thousands of patients living with heart failure and renal disease,” Managing Director and CEO Richard Carreon said.
Previously, the SOZO device was used to assess patients with secondary lymphoedema (swelling in the arms and legs) and give an accurate reading of the fluid status.
Once a patient knows their levels, clinicians can provide individualised care to help improve outcomes.
Despite this advance, ImpediMed shares are only up a slight 2.86 per cent and trading for 3.6 cents each at 2:11 pm AEST.
